交易中 11-18 10:57:12 美东时间
-0.004
-1.56%
CorMedix acquires Heron Therapeutics assets for $222.6 million upfront, adding four commercial hospital therapies to expand its acute care reach.
11-10 01:09
Adds four commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — to CorMedix's hospital- and acute-care-focused commercial platformUpfront consideration consisting of $145 million in cash, subject
11-09 20:07
Needham analyst Serge Belanger downgrades Heron Therapeutics (NASDAQ:HRTX) from Buy to Hold.
06-03 18:16
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintains $5 price target.
2024-09-26 01:42